



Response to Office Action
Application No. 10/047,935
Page 1 of 3
25212.0115-07

Gp/1624
#9/C
4/1/03
C.5h

Certificate of Mailing:

The undersigned certifies that this correspondence is being deposited this 14th day of February, 2003, as first-class mail, postage prepaid, in an envelope addressed to the Commissioner For Patents, Washington, DC 20231.

(s)

Elsa Djuardi

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Varney et al

Examiner: Rao, Deepak. R

SERIAL NO.: 10/047,935

Unit: 1624

FILED: 10/23/2001

FOR: ANTIPROLIFERATIVE SUBSTITUTED 5-
THIAPYRIMIDINONE AND 5-
SELENOLYRIMIDINONE COMPOUNDS

Commissioner of Patents
Washington, D.C. 20231

Sir:

RECEIVED
MAR 03 2003
TECH CENTER 1600/2900

AMENDMENTS

This document responds to the Office Action in the above case mailed November 18, 2002, requiring a response by February 18, 2003. Accordingly this amendment is filed timely.

Please amend the application as follows:

CLEAN COPY - PLEASE ENTER

In the Claims:

Please delete claims 52 and 54-61 without prejudice or disclaimer.

Please add new claim 62 as follows:

62. (New) A compound selected from the group consisting of:

N-[4-[3-(2,6-diamino-4(3H)-oxopyrimidin-5-yl)thio]propyl]benzoyl-(S)-glutamic acid;

N-[4-(N-[2-([2,6-diamino-4(3H)-oxopyrimidin-5-yl]thio)ethyl]amino)benzoyl]-S-glutamic acid;

N-[(4-[2-([2,6-diamino-4(3H)-oxopyrimidin-5-yl]thio)ethyl]thio)benzoyl]-S-glutamic acid;

N-[2-(5-[3-([2,6-diamino-4(3H)-oxopyrimidin-5-yl]thio)propyl]-thienoyl)]-(S)-glutamic acid;